Orion Oyj B
Research Orion Oyj B (ORNBV) on Bullrun: valuation model: 33.7% undervalued, market cap EUR 10.00B, P/E 18.9, dividend yield 2.6%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerORNBV
- ExchangeHE
- CountryFinland
- SectorHealthcare
- IndustryDrug Manufacturers - General
- CurrencyEUR
- Valuation signal33.7% undervalued
- Market capEUR 10.00B
- P/E18.9
- Dividend yield2.6%
- Financial periodQ1 2026
- RevenueEUR 417.70M
- Net incomeEUR 90.40M
- Free cash flowEUR 16.50M
- Gross margin60.8%
Valuation Snapshot
Bullrun's latest valuation model marks Orion Oyj B as 33.7% undervalued; latest market cap is EUR 10.00B; P/E is 18.9; dividend yield is 2.6%.
About Orion Oyj B
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. It offers pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer;
Frequently asked questions
Is Orion Oyj B overvalued or undervalued?
Bullrun's valuation model currently marks Orion Oyj B as 33.7% undervalued.
What is Orion Oyj B's market cap?
Orion Oyj B's market capitalization is EUR 10.00B.
What is Orion Oyj B's P/E ratio?
Orion Oyj B's price-to-earnings (P/E) ratio is 18.9.
Does Orion Oyj B pay a dividend?
Orion Oyj B has a dividend yield of 2.6%.
What does Orion Oyj B do?
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. It offers pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer;